Start Time: 09:00 January 1, 0000 10:01 AM ET
CureVac N.V. (NASDAQ:CVAC)
Q3 2022 Earnings Conference Call
November 16, 2022, 09:00 AM ET
Company Participants
Franz-Werner Haas - CEO
Pierre Kemula - CFO
Ulrike Gnad-Vogt - Interim Chief Development Officer
Ronald Plasterk - SVP Science & Innovation
Sarah Fakih - VP Corporate Communications and IR
Conference Call Participants
Geoff Meacham - Bank of America
Evan Wang - Guggenheim
Jonathan Miller - Evercore
Roy Buchanan - JMP Securities
Zhiqiang Shu - Berenberg
Operator
Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Sarah Fakih, Vice President Corporate Communications and Investor Relations. Thank you. You may begin.
Sarah Fakih
Thank you. Good morning, good afternoon and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers.
On the call with me from CureVac are Franz-Werner Haas, the Chief Executive Officer; Ulrike Gnad-Vogt, our Interim Chief Development Officer; Ronald Plasterk, our Senior Vice President Science & Innovation; and Pierre Kemula, Chief Financial Officer of CureVac. Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our Web site.
Before we begin, a few forward-looking statements. The discussions and responses to your questions on this call reflect management's view as of today, Wednesday, November 16, 2022. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. CureVac disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the U.S. Securities and Exchange Commission.
I will now turn the call over to Franz.
Franz-Werner Haas
Thank you, Sarah. Ladies and gentlemen, a warm welcome to this conference call from us here at CureVac. 2022 has been a highly productive year for our company. We have significantly grown our operational bandwidth across the organization and most importantly our three core competencies; pro technology platform, robust product development pipeline and large GMP manufacturing capacities.